GlaxoSmithKline got more good news about its malaria vaccine today.
Earlier trials involving the vaccine, RTS, S, had focused more on safety than effectiveness.
The results are from a phase III trial, one of the final stages the vaccine must go through before GSK files to get the drug approved by regulators.
GSK, which is based in Britain but has its North American headquarters in Research Triangle Park, has spend hundreds of millions of dollars developing a malaria vaccine over the past two decades.
It is one of a number of pharmaceutical companies that has shifted more and more of its focus to vaccines in recent years.
Two years ago, GSK opened a state-of-the-art vaccine packaging plant west of Philadelphia.
The company, which employs about 4,000 people in RTP, reports third quarter earnings on Oct. 26.